ABSTRACT
Inflammatory myofibroblastic tumor (IMT) is a rare disease that mainly
involves the lung and the abdomen with an intermediate clinical course
but a recurrence rate between 15-30%.
Radical surgery represents the golden standard of treatment, while
chemotherapy and radiotherapy are considered for unresectable lesions.
The identification of ALK translocations in IMT opened the option for
the use of target therapies1. Indeed, the ALK
inhibitors have changed the treatment approach for aggressive lesions,
improving the prognosis.
Intraluminal upper way IMT is extremely rare and represents a medical
challenge.
We reported an endotracheal IMT case presenting a before unknown
TRAF3-ALK fusion transcript.